Big Pharma's Secret Weapon: Medicare Starts to Pay Off-Quietly
This article was originally published in RPM Report
Executive Summary
Pharma companies say Part D is a simple trade: increased volume in exchange for decreased prices. Six months into the program, the deal is working out very well for manufacturers-but don't expect anyone to celebrate just yet.
You may also be interested in...
Death to the Primary Care Blockbuster? What 2007 Says About the Future of the Drug Industry
The pharmaceutical industry just had its worst year of growth since 1961, and it doesn't look like there are enough primary care blockbuster launches in 2008 to turn those numbers around. The big lesson from 2007: specialty care is increasingly where pharma needs to be.
The Part D Peak: Big Pharma's Blowout Quarter
While many people were watching the Senate grapple with drug price negotiation authority for CMS, Big Pharma blew past Wall Street's expectations with big first quarter gains. One year into the program, Medicare is definitely paying off. But will the party last?
The Part D Peak: Big Pharma's Blowout Quarter
While many people were watching the Senate grapple with drug price negotiation authority for CMS, Big Pharma blew past Wall Street's expectations with big first quarter gains. One year into the program, Medicare is definitely paying off. But will the party last?